Literature DB >> 16000562

A homozygous mutation in MSH6 causes Turcot syndrome.

Madhuri R Hegde1, Belinda Chong, Maria E Blazo, Lip Hon E Chin, Patricia A Ward, Murali M Chintagumpala, John Y Kim, Sharon E Plon, C Sue Richards.   

Abstract

Heterozygous mutations in one of the DNA mismatch repair genes cause hereditary nonpolyposis colorectal cancer (MIM114500). Turcot syndrome (MIM276300) has been described as the association of central nervous system malignant tumors and familial colorectal cancer and has been reported to be both a dominant and recessive disorder. Homozygous and compound heterozygous mutations in APC, MLH1, MSH2, and PMS2 genes have been reported in five families. Here we describe a nonconsanguineous Pakistani family, including a son with lymphoma and colorectal cancer diagnosed at ages 5 and 8, respectively, and an 8-year-old daughter with glioblastoma multiforme. Both children had features of neurofibromatosis type 1 including atypical café au lait spots and axillary freckling without a family history consistent with neurofibromatosis type 1, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer. Mutational analysis was done for MLH1, MSH2, and MSH6 using denaturing high-performance liquid chromatography and sequencing of a blood sample from the daughter. A novel homozygous single base insertion mutation was identified (3634insT) resulting in a premature stop at codon 1,223 in exon 7 of the MSH6 gene. Both parents were found to be heterozygous for the 3634insT mutation. Microsatellite instability testing showed instability in the glioblastoma sample. We report here the first identification of a homozygous mutation in MSH6 in a family with childhood-onset brain tumor, lymphoma, colorectal cancer, and neurofibromatosis type 1 phenotype. Our findings support a role for MSH6 in Turcot syndrome and are consistent with an autosomal recessive mode of inheritance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000562     DOI: 10.1158/1078-0432.CCR-04-2025

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Authors:  Daniel P Cahill; Kymberly K Levine; Rebecca A Betensky; Patrick J Codd; Candice A Romany; Linsey B Reavie; Tracy T Batchelor; P Andrew Futreal; Michael R Stratton; William T Curry; A John Iafrate; David N Louis
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

2.  The hMSH2(M688R) Lynch syndrome mutation may function as a dominant negative.

Authors:  Juana V Martín-López; Ysamar Barrios; Vicente Medina-Arana; Miguel Andújar; Sanghee Lee; Liya Gu; Guo-Min Li; Josef Rüschoff; Eduardo Salido; Richard Fishel
Journal:  Carcinogenesis       Date:  2012-06-27       Impact factor: 4.944

Review 3.  Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term.

Authors:  Jeremy R Jass
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

4.  Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.

Authors:  E Zeynep Erson-Omay; Ahmet Okay Çağlayan; Nikolaus Schultz; Nils Weinhold; S Bülent Omay; Koray Özduman; Yavuz Köksal; Jie Li; Akdes Serin Harmancı; Victoria Clark; Geneive Carrión-Grant; Jacob Baranoski; Caner Çağlar; Tanyeri Barak; Süleyman Coşkun; Burçin Baran; Doğan Köse; Jia Sun; Mehmet Bakırcıoğlu; Jennifer Moliterno Günel; M Necmettin Pamir; Ketu Mishra-Gorur; Kaya Bilguvar; Katsuhito Yasuno; Alexander Vortmeyer; Anita J Huttner; Chris Sander; Murat Günel
Journal:  Neuro Oncol       Date:  2015-03-03       Impact factor: 12.300

5.  Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.

Authors:  Chen Yang; Frances Austin; Hope Richard; Michael Idowu; Vernell Williamson; Fernanda Sabato; Andrea Ferreira-Gonzalez; Scott A Turner
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

6.  Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium.

Authors:  Melyssa Aronson; Steven Gallinger; Zane Cohen; Shlomi Cohen; Rina Dvir; Ronit Elhasid; Hagit N Baris; Revital Kariv; Harriet Druker; Helen Chan; Simon C Ling; Paul Kortan; Spring Holter; Kara Semotiuk; David Malkin; Roula Farah; Alain Sayad; Brandie Heald; Matthew F Kalady; Lynette S Penney; Andrea L Rideout; Mohsin Rashid; Linda Hasadsri; Pavel Pichurin; Douglas Riegert-Johnson; Brittany Campbell; Doua Bakry; Hala Al-Rimawi; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Uri Tabori; Carol Durno
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

7.  Association of MSH6 mutation with glioma susceptibility, drug resistance and progression.

Authors:  Chaoran Xie; Hansong Sheng; Nu Zhang; Shiting Li; Xiangyu Wei; Xuesheng Zheng
Journal:  Mol Clin Oncol       Date:  2016-05-20

Review 8.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

9.  Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.

Authors:  Susanne Magnusson; Ake Borg; Ulf Kristoffersson; Mef Nilbert; Thomas Wiebe; Håkan Olsson
Journal:  Fam Cancer       Date:  2008-05-15       Impact factor: 2.375

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.